-- 根據週四提交給澳洲證券交易所的文件，Articore集團（ASX：ATG）公佈其第三財季毛利為3,280萬澳元，較去年同期的3,220萬澳元增長1.6%。 截至3月31日的季度，付費獲客後的毛利（GPAPA）年減3.4%至1,950萬澳元，而去年同期為2,020萬澳元。 GPAPA利潤率接近31%，較去年同期成長160個基點。 截至3月31日的季度，市場平台營收年減8.5%至6,320萬澳元，去年同期為6,900萬澳元。 該公司重申了其財年展望，預計GPAPA利潤率為27%至29%，息稅前利潤在600萬澳元至1000萬澳元之間。預計本財年基本現金流將達800萬澳元至1,200萬澳元。 該公司股價在上週四的交易中上漲了2%。
Related Articles
Asia
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
$SGX:CC3
Asia
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
$BOM:544632$NSE:MEESHO
Asia
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.
$SHE:000661